IRIS
IACOBELLI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.609
EU - Europa 1.043
AS - Asia 600
SA - Sud America 23
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
Totale 18.312
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.599
KR - Corea 280
CN - Cina 243
UA - Ucraina 200
SE - Svezia 173
IE - Irlanda 161
IT - Italia 151
DE - Germania 120
GB - Regno Unito 98
FI - Finlandia 50
FR - Francia 28
JP - Giappone 22
CO - Colombia 15
RU - Federazione Russa 15
GH - Ghana 12
NL - Olanda 11
BE - Belgio 10
HK - Hong Kong 10
IN - India 9
CA - Canada 8
EU - Europa 8
AU - Australia 7
GR - Grecia 5
IR - Iran 5
EG - Egitto 4
ES - Italia 4
PK - Pakistan 4
AR - Argentina 3
BR - Brasile 3
CZ - Repubblica Ceca 3
IL - Israele 3
JO - Giordania 3
MA - Marocco 3
MY - Malesia 3
NO - Norvegia 3
PH - Filippine 3
TR - Turchia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
MX - Messico 2
PL - Polonia 2
RO - Romania 2
RS - Serbia 2
SA - Arabia Saudita 2
TH - Thailandia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BG - Bulgaria 1
CH - Svizzera 1
DK - Danimarca 1
ID - Indonesia 1
IQ - Iraq 1
KZ - Kazakistan 1
MD - Moldavia 1
NP - Nepal 1
SG - Singapore 1
ZA - Sudafrica 1
Totale 18.312
Salva come PNG Salva come JPEG
Città #
Woodbridge 4.667
Wilmington 4.368
Houston 4.068
Fairfield 666
Ann Arbor 388
Ashburn 293
Seattle 274
Chandler 271
Cambridge 247
Creede 202
Dublin 155
Jacksonville 149
Medford 134
Beijing 72
Rome 70
Santa Clara 67
Lawrence 61
Dearborn 57
Zhengzhou 40
Nanjing 38
San Diego 31
New York 30
Milan 26
Redwood City 26
London 25
Philadelphia 22
Scottsdale 21
Shanghai 19
Petaluma 18
Accra 12
Seoul 12
Mülheim 11
Brussels 10
Norwalk 10
Bogotá 8
Boardman 7
Kilburn 7
Nanchang 7
Pereira 7
Roppongi 7
Hefei 6
Helsinki 6
Kunming 6
Wuhan 6
Center 5
Chicago 5
Geumcheon-gu 5
Haeundae-gu 5
Hong Kong 5
Las Vegas 5
Naples 5
Richardson 5
Toronto 5
Engelhard 4
Enterprise 4
Falls Church 4
Guangzhou 4
Hounslow 4
Kendall Park 4
Menlo Park 4
Mountain View 4
Thessaloniki 4
Verona 4
Yalta 4
Amman 3
Bologna 3
Brooklyn 3
Cagayan de Oro 3
Casablanca 3
City of Westminster 3
Coimbatore 3
Dortmund 3
Fuzhou 3
Groningen 3
Hangzhou 3
Hebei 3
Kyoto 3
Phoenix 3
Redmond 3
Shenyang 3
Sioux Falls 3
St. George 3
Tel Aviv 3
Tokyo 3
University Park 3
Amsterdam 2
Berlin 2
Bethesda 2
Birmingham 2
Cairo 2
Central District 2
Chengdu 2
Cluj-Napoca 2
Council Bluffs 2
Croydon 2
Delhi 2
Espoo 2
Ferrara 2
Foggia 2
Fort Worth 2
Totale 16.809
Salva come PNG Salva come JPEG
Nome #
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial) 605
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT) 487
Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation 453
Salvage use of allogeneic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the EBMT Chronic Malignancies Working Party 413
Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study 403
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study 403
Multiple time scales in multi-state models 402
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. 399
Outcome of patients developing GvHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT 391
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. 387
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research 386
Efficacy and outcome of autologous transplantation in rare myelomas 385
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation 381
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation 381
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia 378
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia 378
Current practices used for the prevention of central venous catheter-associated infection in hematopoietic stem cell transplantation recipients: a survey from the Infectious Diseases Working Party and Nurses' Group of EBMT 377
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia 372
Partially anaortic clampless off-pump coronary artery bypass prevents neurologic injury compared to on-pump coronary surgery: a propensity score-matched study on 286 patients 372
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? 369
Assessment of the role of timing of second transplantation in multiple myeloma by multistate modeling 368
Protective Environment for Hematopoietic Cell Transplant (HSCT) Recipients: The Infectious Diseases Working Party EBMT Analysis of Global Recommendations on Health-Care Facilities 368
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties 365
Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in myeloma: long-term follow-up 363
Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia 362
Stem cell transplantation for chronic myeloid leukemia in children 361
Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 358
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 358
The Cox shared frailty model with log-skew-normal frailties 349
Length of stay in different drug using states: lifestyles of problem and recreational drug consumers 348
Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study 344
Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation 344
High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation 341
Survival probabilities with time-dependent treatment indicator: quantities and non-parametric estimators 336
Lymphoproliferative Disorders After Hematopoietic Stem Cell Transplantation in Children and Adults: a Study From the Infectious Diseases Working Group of the European Group for Blood and Marrow Transplantation 333
Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents. 329
Melphalan 140mg/M2 Or 200mg/M2 For Autologous Transplantation In Myeloma: Results From The Collaboration To Collect Autologous Transplant Outcomes In Lymphoma And Myeloma (CALM) Study. A Report By The EBMT Chronic Malignancies Working Party 328
Allogenic hematopoietic stem cell transplantation in patients with polycythemia or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: report from the MPN subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 326
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group 322
Impact of complete remission before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial 319
Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation 319
Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia 316
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT 314
Primary plasma cell leukemia and autologous stem cell transplantation 305
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. 300
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. 285
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion 282
Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma 255
Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita 225
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL) 104
Allogeneic transplantation in multiple myeloma - Does it still have a place? 84
Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP 58
Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT) 52
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy 44
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT 42
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT 41
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation 41
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors 41
Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: a study on behalf of the European blood and marrow transplant severe aplastic anemia working party. 39
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling 38
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor 35
Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 35
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation 34
Analyzing differences between restricted mean survival time curves using pseudo-values 32
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101 30
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study 26
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT 26
Pollen variability in Quercus L. species and relative systematic implications 25
Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: risk factors and association with mortality 25
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT 25
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study 24
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia 20
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP 20
Impact of donor-derived CD34+infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT 18
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma 14
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT 13
Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation 13
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation 12
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma 12
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia 12
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes 10
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications 10
Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study 10
Outcomes and toxicity of allogeneic HCT in CML patients previously treated with second generation TKIs: a prospective non-interventional study from the Chronic Malignancy Working Party of EBMT 9
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors 8
Role of stem cell transplantation in myeloma 8
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants 8
The effect of prior exposure to imatinib on transplant-related mortality 8
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning 8
Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation 7
Statistical methods in HSCT and cellular therapies 7
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison 4
Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia 3
Totale 18.780
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.359
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.359
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.116 0 0 0 0 0 0 0 0 0 0 580 536
2019/20204.844 424 412 337 492 408 523 416 408 452 381 300 291
2020/20213.012 270 312 297 311 257 505 512 213 86 96 124 29
2021/2022778 41 87 85 53 21 51 43 27 35 56 58 221
2022/20231.382 89 77 40 77 76 206 412 229 78 18 44 36
2023/2024326 34 18 29 28 45 54 34 22 32 28 2 0
Totale 18.780